ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.
| Revenue (Most Recent Fiscal Year) | $8.28B |
| Net Income (Most Recent Fiscal Year) | $791.47M |
| PE Ratio (Current Year Earnings Estimate) | 11.32 |
| PE Ratio (Trailing 12 Months) | 10.78 |
| PEG Ratio (Long Term Growth Estimate) | 1.50 |
| Price to Sales Ratio (Trailing 12 Months) | 1.42 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.16 |
| Pre-Tax Margin (Trailing 12 Months) | 10.10% |
| Net Margin (Trailing 12 Months) | 9.25% |
| Return on Equity (Trailing 12 Months) | 11.46% |
| Return on Assets (Trailing 12 Months) | 6.49% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.36 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $117.92 |
| Earnings per Share (Most Recent Fiscal Quarter) | $3.07 |
| Earnings per Share (Most Recent Fiscal Year) | $13.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $9.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 80.76M |
| Free Float | 45.22M |
| Market Capitalization | $11.60B |
| Average Volume (Last 20 Days) | 1.08M |
| Beta (Past 60 Months) | 1.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 44.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.61% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |